Portfolio

We have built up an exciting portfolio of investments in high potential businesses across a range of therapeutic areas, technologies, geographies and clinical contexts. 

 

Title

Stage

Technology Area

Company's status

Logo List

News

  • 11 July 2017

    Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

  • 11 July 2017

    Clearside Biomedical Announces First Patient Randomized in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a phase 2 clinical trial (“TYBEE”) of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”), Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of diabetic macular edema (“DME”).